Author:
Jie H-B,Gildener-Leapman N,Li J,Srivastava R M,Gibson S P,Whiteside T L,Ferris R L
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A (2013) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32: 1743–1751.
2. Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, Parmiani G, Belli F, Rivoltini L, Castelli C (2010) LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumour sites. J Immunol 184: 6545–6551.
3. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F (2007) A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204: 1757–1764.
4. Darrasse-Jeze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, Cohen JL, Bellier B, Podsypanina K, Klatzmann D (2009) Tumour emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumours in mice. J Clin Invest 119: 2648–2662.
5. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2008) The prognostic value of FoxP3+ tumour-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18: 3022–3029.
Cited by
229 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献